Dachaigh › Myeloma iomaill › Colorado
Sgrùdaidhean clionaigeach Myeloma iomaill ann an Colorado
Tha 37 sgrùdaidhean airson Myeloma iomaill a’ lorg phàirtichean aig làraichean ann an Colorado.
Bailtean ann an Colorado
Teacsa sgrùdaidh oifigeil (Beurla)
A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
- Colorado Blood Cancer Institute, Denver
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 1 Dàmh 2026 · NCT07589634A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
- Local Institution - 0381, Aurora
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 30 Sult 2026 · NCT05519085A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Research Site, Denver
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 29 Sult 2026 · NCT07391657A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
- Colorado Blood Cancer Institute /ID# 280275, Denver
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 29 Sult 2026 · NCT07409246A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
- Colorado Blood Cancer Institute, Denver
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 28 Sult 2026 · NCT05652335A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- Colorado Blood Cancer Institute, Denver
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT07258511A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Colorado Blood Cancer Institute, Denver
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT07518186A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
- Research Site, Denver
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT07073547A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
- Colorado Blood Cancer Institute, Denver
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT06500884A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma
- Colorado Blood Cancer Institute, Denver
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT06768489A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
- Colorado Blood Cancer Institute /ID# 279080, Denver
A’ fastadhÌre 2/3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 22 Sult 2026 · NCT07095452Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- CBCI, Colorado Blood Cancer Institute, Denver
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 21 Sult 2026 · NCT07648264A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
- Colorado Blood Cancer Institute (CBCI) at Presbyterian/ St. Luke's Medical Center, Denver
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 17 Sult 2026 · NCT04910568Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Colorado Blood Cancer Institute, Denver
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 14 Sult 2026 · NCT06297226A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma
- Colorado Blood Cancer Institute, Denver
- Rocky Mountain Cancer Center, Denver
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 4 Sult 2026 · NCT07637578A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
- Research Site, Denver
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 27 Lùna 2026 · NCT07681596MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- UCHealth Poudre Valley Hospital, Fort Collins
- UCHealth Harmony, Fort Collins
- UCHealth Greeley Hospital, Greeley
- agus 3 a bharrachd
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 24 Lùna 2026 · NCT06152575Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- Penrose-Saint Francis Healthcare, Colorado Springs
- Rocky Mountain Cancer Centers-Penrose, Colorado Springs
- Saint Francis Cancer Center, Colorado Springs
- agus 3 a bharrachd
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 19 Lùna 2026 · NCT04566328A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
- Colorado Blood Cancer Institute/SCRI, Denver
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 18 Lùna 2026 · NCT06292780AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
- Research Site, Aurora
- Research Site, Denver
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 17 Lùna 2026 · NCT05850234Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Research Site, Aurora
- Research Site, Denver
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 14 Lùna 2026 · NCT07764978A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
- Colorado Blood Cancer Institute /ID# 273129, Denver
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 21 Iuch 2026 · NCT06892522Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
- Colorado Blood Cancer Institute, Denver
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 16 Iuch 2026 · NCT05469893A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Rocky Mountain Cancer Centers - Aurora /ID# 268574, Aurora
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 13 Iuch 2026 · NCT05650632Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
- UCHealth Poudre Valley Hospital, Fort Collins
- UCHealth Harmony, Fort Collins
- UCHealth Greeley Hospital, Greeley
- agus 3 a bharrachd
A’ fastadhÌre 4
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 1 Iuch 2026 · NCT06057402Integrated Cancer Repository for Cancer Research
- Advent Health, Greenwood Village
A’ fastadhSgrùdadh amharcFàilte do shaor-thoilich fhallain
Aoisean 19 gu 110 · Gach gnè · Air ùrachadh 29 Ògmh 2026 · NCT02012699Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
- Rocky Mountain Regional VA Medical Center, Aurora
- Penrose-Saint Francis Healthcare, Colorado Springs
- Rocky Mountain Cancer Centers-Penrose, Colorado Springs
- agus 6 a bharrachd
A’ fastadhÌre 3
Gach aois · Gach gnè · Air ùrachadh 10 Ògmh 2026 · NCT05561387Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- University of Colorado Hospital, Aurora
- Colorado Blood Cancer Institute, Denver
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 4 Ògmh 2026 · NCT05243797Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
- Colorado Blood Cancer Institute, Denver
A’ fastadhÌre 2
Aoisean 19 agus nas sine · Gach gnè · Air ùrachadh 4 Ògmh 2026 · NCT06974786A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
- Colorado Blood Cancer Institute/SCRI, Denver
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 13 Cèit 2026 · NCT05828511Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Colorado Blood Cancer Institute /ID# 273751, Denver
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 12 Cèit 2026 · NCT06896916A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
- GSK Investigational Site, Aurora
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 22 Gibl 2026 · NCT06679101Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
- Colorado Blood Cancer Institute, Denver
- Rocky Mountain Cancer Center, Denver
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 22 Gibl 2026 · NCT05972135Survivors Uniting for Remote Guided Exercise
- Human Performance Clinical Research Lab, Fort Collins
A’ fastadh
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 31 Màrt 2026 · NCT07290309A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Colorado Blood Cancer Institute, Denver
A’ fastadhÌre 1/2
Aoisean 12 agus nas sine · Gach gnè · Air ùrachadh 24 Màrt 2026 · NCT04988555A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
- Colorado Blood Cancer Institute, Denver
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 18 Màrt 2026 · NCT06153251CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
- CU Anschutz Medical Campus, Anshutz Cancer Pavillion, Aurora
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 25 Sult 2025 · NCT05722418Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.